<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5156">
  <stage>Registered</stage>
  <submitdate>31/08/2015</submitdate>
  <approvaldate>31/08/2015</approvaldate>
  <nctid>NCT02547935</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD</studytitle>
    <scientifictitle>An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D1690C00023</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus, CKD and Albuminuria</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dapagliflozin 10 mg
Treatment: drugs - Dapagliflozin 10mg+Saxagliptin 2.5mg
Treatment: drugs - Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg

Experimental: Dapagliflozin 10mg - Tablets administered orally once daily for 24 weeks

Experimental: Dapagliflozin 10mg + Saxagliptin 2.5mg - Tablets administered orally once daily for 24 weeks

Placebo Comparator: Placebo - Tablets administered orally once daily for 24 weeks


Treatment: drugs: Dapagliflozin 10 mg
Tablets administered orally once daily for 24 weeks.

Treatment: drugs: Dapagliflozin 10mg+Saxagliptin 2.5mg
Tablets administered orally once daily for 24 weeks.

Treatment: drugs: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Tablets administered orally once daily for 24 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in HbA1c (dapagliflozin 10 mg + saxagliptin 2.5 mg) - To compare the mean change from baseline to week 24 in HbA1c between dapagliflozin 10 mg plus saxagliptin 2.5 mg and placebo</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percent change in Urine albumin to creatinine ratio (UACR) (dapagliflozin 10 mg + saxagliptin 2.5 mg) - To compare the mean persent change from baseline to week 24 in Urine albumin to creatinine ratio (UACR) between dapagliflozin 10 mg plus saxagliptin 2.5 mg and placebo.</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percent change in Urine albumin to creatinine ratio (UACR) (dapagliflozin 10 mg) - To compare the mean percent change from baseline to week 24 in Urine albumin to creatinine ratio (UACR)between dapagliflozin 10 mg and placebo</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in total body weight - To compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo.</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in FPG - To compare the mean change from baseline in fasting plasma glucose (FPG) between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo.</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients that achieve 30% reduction in UACR - To compare the proportion of patients achieving a 30% reduction in UACR between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients which achieve HbA1c&lt;7% - To compare the proportion of patients achieving a reduction in HbA1c &lt;7.0% between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in seated SBP - To compare the mean change from baseline in seated systolic blood pressure (SBP) between dapagliflozin 10 mg with and, separately, without saxagliptin 2.5 mg and placebo</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HbA1c - To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo</outcome>
      <timepoint>From baseline up to 24 weeks of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of informed consent prior to any study specific procedures

          -  Female or male aged =18 years

          -  History of type 2 diabetes mellitus for more than 12 months

          -  HbA1c=7.0% and =11.0%

          -  Stable antidiabetic treatment during the last 12 weeks up to randomization

          -  eGFR 25-75 mL/minute/1.73m2, inclusive

          -  Micro or macroalbuminuria (UACR 30 - 3500 mg/g)

          -  Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening

          -  Body mass index between 20 and 45 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>130</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any of the following CV/Vascular Diseases within 3 month prior to signing the consent
             at Visit 1:

               -  Myocardial infarction

               -  cardiac surgery or revascularization (CABG/PTCA)

               -  unstable angina

               -  unstable HF

               -  New York Heart Association (NYHA) Class III-IV

               -  transient ischemic attack (TIA) or significant cerebrovascular disease

               -  unstable or previously undiagnosed arrhythmia

          -  Significant hepatic disease, including, but not limited to, chronic active hepatitis
             and/or severe hepatic insufficiency

          -  Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) &gt; 3X ULN

          -  Total Bilirubin (TB) &gt;2 mg/dL (34.2 Âµmol/L)

          -  History of acute kidney injury requiring renal replacement therapy (dialysis or
             ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other
             than diabetic nephropathy or diabetic nephropathy with nephrosclerosis

          -  Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors

          -  Any condition which, in the judgment of the Investigator, may render the patient
             unable to complete the study or which may pose a significant risk to the patient or
             patient suspected or with confirmed poor protocol or medication compliance</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>21/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>458</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>28/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Box Hill</hospital>
    <hospital>Research Site - Campbelltown</hospital>
    <hospital>Research Site - Geelong</hospital>
    <hospital>Research Site - Herston</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>2560 - Campbelltown</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>4029 - Herston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chuo-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hachioji-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Higashiosaka-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kisarazu-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Neyagawa-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nishinomiya-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Oita-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sendai-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shinjuku-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Toyonaka-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Ansan-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Wonju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Del. Cuauhtemoc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>MÃ©xico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Queretaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Zapopan, Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Zapopan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Benoni</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kuilsrivier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Mamelodi East</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Muckleneuk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Paarl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A CoruÃ±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sabadell (Barcelona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago(A CoruÃ±a)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung Hsien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>New Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>New Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Yong-Kang City</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this clinical research study is to determine whether dapagliflozin alone or in
      combination with saxagliptin can decrease albuminuria and improve glycemic control in
      patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned
      to randomize a total of 450 patients (150 patients per treatment arm).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02547935</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>